Alivus

Founded: 2011 • Age: 15 yrs Listed
High-value APIs are developed and manufactured for global partners.
Request Access
Report Incorrect Data
Page last updated

About Alivus

Alivus is a publicly listed company founded in 2011. High-value APIs are developed and manufactured for global partners. The company has 2,021 employees. Its Indian entity Alivus Life Sciences Limited reported revenue of ₹2,612 Cr. Alivus offers products and services including Active Pharmaceutical Ingredients and CDMO Services. Its focus areas include Traditional Pharmaceuticals.

Company details

High-value Active Pharmaceutical Ingredients (APIs) are developed and manufactured by Alivus within the pharmaceutical sector. APIs are supplied to worldwide partners, with emphasis placed on chronic therapeutic areas. End-to-end support is extended through process development, analytical development, and production of APIs and intermediates. Contract development and manufacturing services are provided to clients. Research and development activities are conducted to support medicine quality standards.

Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹17,753 Cr

    ALIVUS · NSE

  • Share Price
    ₹1,474.70

    +2.15% today

  • Revenue
    ₹2,552 Cr

    FY 2025-26 · +6.9% YoY

  • EBITDA
    ₹772 Cr

    Margin 30.2%

  • Net Profit
    ₹550 Cr

    FY 2025-26 · +14.9% YoY

  • P/E (TTM)
    15.2x

    P/B 2.9x

  • ROE
    18.4%

    ROCE 23.9%

  • Debt / Equity
    0.02

    Interest cover 0.8x

  • Employee Count
    2,021

Products & Services of Alivus

Alivus offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients and CDMO Services.

Active Pharmaceutical Ingredients
Pharmaceutical Products

High-value APIs are developed and manufactured for non-commoditized applications in chronic areas

CDMO Services
Contract Services

End-to-end support is provided for API production and development processes

Board of directors of Alivus Life Sciences Limited (Alivus)

Alivus Life Sciences Limited is the primary company behind Alivus. The board of Alivus Life Sciences Limited currently have 7 directors; the longest-serving is Yasir Yusufali Rawjee, appointed in 2019. 15 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Yasir Yusufali Rawjee
DIN 01965174
Managing Director26 Sep 20197 yrs 1 moAlivus Life Sciences Limited
Taruvai Laxminarayanan Easwar
DIN 03135959
Director08 Mar 20215 yrs 8 moAlivus Life Sciences Limited
Manju Agarwal
DIN 06921105
Director08 Mar 20215 yrs 8 moAlivus Life Sciences Limited
Vinod Naik
DIN 03635487
Whole-time director21 Oct 20224 yrsAlivus Life Sciences Limited
Kaushikbhai Nandubhai Patel
DIN 00145086
Director06 Mar 20242 yrs 8 moAlivus Life Sciences Limited
Hiren Karsanbhai Patel
DIN 00145149
Director06 Mar 20242 yrs 8 moAlivus Life Sciences Limited
Savan Rashmikant Godiawala
DIN 07874111
Director25 Apr 20242 yrs 6 moAlivus Life Sciences Limited

People of Alivus

7 people are tracked at Alivus (5 in leadership, 2 in team); the tracked headcount is 2,021.

NameRoleGroup
Raghu Palle
Executive Vice PresidentLeadership
Pravin Thakur
General Manager Human ResourcesLeadership
Yasir Rawjee
Chief Executive OfficerLeadership
Dilip Bhangale
Deputy General ManagerLeadership
Sumantra Mitra
Sr.vice President- Human ResourcesLeadership
Hardik Patel
Mechanical EngineerTeam
Divyesh Dabhade
Technology Transfer ExecutiveTeam
Premium access

Complete people profiles for Alivus

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Alivus

Alivus is a publicly listed company on the NSE with ticker symbol ALIVUS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date06 Aug 2021
  • Listed onNSE: ALIVUS
  • Listed entityAlivus Life Sciences Ltd
  • Exchange sectorHealth technology

Financials of Alivus

Exchange-reported figures of Alivus Life Sciences Limited, the listed company behind Alivus (NSE: ALIVUS).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹2,552 Cr
+6.9% YoY
EBITDA
₹772 Cr
+13.0% YoY
Profit After Tax
₹550 Cr
+14.9% YoY
Net Worth
₹3,332 Cr
+18.3% YoY
Total Assets
₹3,425 Cr
+18.4% YoY
Total Debt
₹56.77 Cr
+0.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,5522,3872,2832,1612,1231,8851,537
Revenue growth+6.9%+4.5%+5.6%+1.8%+12.6%+22.6%-
EBITDA772683674642616591472
EBITDA margin+30.2%+28.6%+29.5%+29.7%+29.0%+31.4%+30.7%
Profit before tax751654631629565471421
Net profit550478471467419352314
Net profit margin+21.5%+20.0%+20.7%+21.6%+19.8%+18.7%+20.4%
EPS (₹)45.9939.6338.4338.1134.17358.761,597.44
Balance sheet
Total assets3,4252,8932,3652,1652,057753402
Net worth3,3322,8172,3322,1382,054753402
Total debt56.7756.6117.1519.362.880.000.02
Cash & bank2.1371.2430230951211610.00
Net working capital1,3691,3931,4801,3561,382178(147)
Cash flow
Cash from operations565392414306598388195
Cash from investing(570)(616)(116)(147)(122)(68.73)(50.52)
Cash from financing(64.34)(6.23)(279)(388)(78.80)(214)(137)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue682640689673588602650642
Revenue growth (YoY)+16.0%+6.4%+6.1%+4.8%+16.0%+2.3%--
Other income19.9222.4022.7813.9314.728.9910.0910.46
Total expenses417429475467409430451452
EBITDA265212215206179172198190
EBITDA margin+38.9%+33.1%+31.1%+30.6%+30.5%+28.6%+30.6%+29.6%
Depreciation21.8220.5920.2019.6618.4417.0615.9715.16
Interest1.311.311.311.491.321.251.260.46
Profit before tax262212216198174163191185
Tax65.2352.1453.1448.1344.1141.4549.4348.19

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue682640689673588602650642
Revenue growth (YoY)+16.0%+6.4%+6.1%+4.8%+16.0%+2.3%--
Other income19.9222.4022.7813.9314.728.9910.0910.46
Total expenses417429475467409430451452
EBITDA265212215206179172198190
EBITDA margin+38.9%+33.1%+31.1%+30.6%+30.5%+28.6%+30.6%+29.6%
Depreciation21.8220.5920.2019.6618.4417.0615.9715.16
Interest1.311.311.311.491.321.251.260.46
Profit before tax262212216198174163191185
Tax65.2352.1453.1448.1344.1141.4549.4348.19
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,5522,3872,2832,1612,1231,8851,537
Revenue growth+6.9%+4.5%+5.6%+1.8%+12.6%+22.6%-
Other income60.4134.5712.0428.9614.700.8111.99
Total expenses1,7801,7041,6091,5191,5071,2941,065
Employee cost272252258180169149142
EBITDA772683674642616591472
EBITDA margin+30.2%+28.6%+29.5%+29.7%+29.0%+31.4%+30.7%
Depreciation75.3660.6153.4542.0937.8833.3929.37
Interest5.372.411.550.5527.9687.5533.52
Profit before tax751654631629565471421
Tax187168160162146119108
Net profit550478471467419352314
Net profit margin+21.5%+20.0%+20.7%+21.6%+19.8%+18.7%+20.4%
EPS (₹)45.9939.6338.4338.1134.17358.761,597.44
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.5524.5124.5124.5124.511.961.96
Reserves & surplus3,3082,7932,3082,1142,030751400
Shareholders' funds (net worth)3,3322,8172,3322,1382,054753402
Secured loans0.000.000.000.000.000.000.00
Unsecured loans56.7756.6117.1519.362.880.000.02
Total debt56.7756.6117.1519.362.880.000.02
Total liabilities3,4252,8932,3652,1652,057753402
Assets
Gross block1,3671,2191,012936711652595
Net block1,038955805781595573546
Capital work in progress28410210661.6291.6914.1010.73
Investments7804780.080.080.080.080.08
Inventories692674667604516513413
Sundry debtors1,073970765807673620639
Cash & bank balances2.1371.2430230951211610.00
Loans & advances10214318213062.6915198.71
Total current assets1,8691,8581,9161,8501,7651,3991,160
Total current liabilities5004654364943821,2211,307
Net working capital1,3691,3931,4801,3561,382178(147)
Total assets3,4252,8932,3652,1652,057753402
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash71.0630128451211610.002.06
Net cash from operating activities565392414306598388195
Net cash from investing activities(570)(616)(116)(147)(122)(68.73)(50.52)
Net cash from financing activities(64.34)(6.23)(279)(388)(78.80)(214)(137)
Net change in cash(69.08)(230)17.59(228)3971067.94
Closing cash2.1371.2430230951211610.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.9%+4.5%+5.6%+1.8%+12.6%+22.6%-
EBITDA growth+13.0%+1.2%+5.0%+4.3%+4.2%+25.2%-
PBT growth+14.9%+3.6%+0.4%+11.3%+20.0%+11.9%+84.4%
Net income growth+14.9%+1.5%+0.9%+11.5%+19.1%+12.1%-
Revenue CAGR (3Y)+5.7%+4.0%+6.6%+12.0%+33.8%+1861.0%-
EBITDA CAGR (3Y)+6.3%+3.5%+4.5%+10.8%+35.5%--
Profitability & leverage
Net income margin+22.1%+20.4%+20.6%+21.6%+19.7%+18.7%+20.4%
Return on capital employed+24.0%+25.0%+27.9%+29.8%+42.2%+96.8%+185.6%
Return on net worth+18.4%+18.9%+21.1%+22.3%+29.8%+60.9%+127.8%
Debt / equity0.020.010.010.010.000.000.00
Long-term debt / equity0.020.010.010.000.000.000.00
Interest cover0.770.390.250.094.8415.707.57
Efficiency & per share
Fixed asset turnover1.972.142.342.623.123.022.87
Inventory turnover3.743.563.593.864.124.073.78
Debtors turnover2.502.752.902.923.283.002.83
EPS (₹)45.9939.6338.4338.1134.17358.761,597.44
Dividend per share (₹)5.005.0022.5042.0021.000.000.00
Book value per share (₹)271.49229.92190.35174.51167.66768.112,049.45

Web traffic of Alivus

The website of Alivus (alivus.com) receives about 5.6K visits a month.

  • Monthly visits
    5.6K

    ▼ 45.7% vs previous month

Similar websites

Websites whose visitors overlap most with Alivus. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Glenmark Life Sciences
glenmarklifesciences.com
100%
View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Alivus

Alivus Life Sciences: Collaborates With IQGen-X Pharma By Signing Shareholders' Agreement And Continues Relationship With Current Shareholders.
Exchange Update • 2 days ago
ALIVUS: Q2 REVENUE 6.82B RUPEES VS 5.9B (YOY)
Exchange Update • 15 days ago
ALIVUS: Q2 SL NET PROFIT 1.97B RUPEES VS 1.3B (YOY)
Exchange Update • 15 days ago
ALIVUS: Q2 EBITDA 2.65B RUPEES VS 1.8B (YOY); Q2 EBITDA MARGIN 38.88% VS 30.46% (YOY)
Exchange Update • 15 days ago
Alivus Life Sciences: Acquires 9.21% Stake In Torrent Urja 19 Private Limited For ₹14.04 Crores To Boost Renewable Energy Focus And Meet Electricity Act Standards.
Exchange Update • 1 month ago
Alivus Life Sciences acquires 76% stake in IQGenX Pharma | Capital Market News - Business Standard
Business Standard • 2 months ago
Alivus Life Sciences To Buy 76% Stake In Iqgen-X Pharma For Approx 91.2 Million Rupees
Reuters • 2 months ago
Restaurant Brands Asia Ltd leads gainers in 'A' group | Capital Market News - Business Standard
Business Standard • 3 months ago
ALIVUS: Strong Q1 growth and margin gains driven by non-GPL and new launches, with robust FY 2027 outlook
Quartr • 3 months ago
Alivus Life Sciences standalone net profit rises 31.71% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 3 months ago
Premium access

Complete news archive for Alivus

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Alivus

Alivus was founded in 2011.

Alivus has 2,021 employees.

The primary company behind Alivus, Alivus Life Sciences Limited, reported revenue of ₹2,612 Cr for FY 2026, up 7% year on year.

High-value Active Pharmaceutical Ingredients (APIs) are developed and manufactured by Alivus within the pharmaceutical sector. APIs are supplied to worldwide partners, with emphasis placed on chronic therapeutic areas. End-to-end support is extended through process development, analytical development, and production of APIs and intermediates. Contract development and manufacturing services are provided to clients. Research and development activities are conducted to support medicine quality standards.

Alivus offers Active Pharmaceutical Ingredients and CDMO Services.

Yes, Alivus is publicly traded on NSE under the ticker symbol ALIVUS.

Alivus operates through Alivus Life Sciences Limited.

The legal entities of Alivus currently have 9 directors, including Yasir Yusufali Rawjee, Taruvai Laxminarayanan Easwar, Rudalf Joseph Corriea and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available